AJKD Blog

Dr. Elias John Elenjickal is a Nephrology Research Fellow and PhD. student at the McGill University Health Centre in Montreal, Canada. He completed his medical degree and internal medicine residency at Goa Medical College, and his nephrology training at Dayanand Medical College, Ludhiana—both in India. He is currently on sabbatical from Christian Medical College (CMC), Vellore, the largest not-for-profit tertiary care institution in South India, where he has served as both a clinician and [...]

Kidney transplant recipients are at least twice as likely to develop cancer compared with immunocompetent people. Cancer is now the second leading cause of death in kidney transplant recipients. In a recent Core Curriculum published in AJKD, the authors review common pretransplant and posttransplant cancers and management strategies to help nephrologists understand and manage the associated risks and optimize diagnosis and treatment. AJKDBlog’s Interviews Editor Timothy Yau chatted with [...]

Dr. Natasha Freeman is an Assistant Professor in Nephrology, specializing in glomerular diseases, at Columbia University Irving Medical Center. She received her MD from the Columbia University Vagelos College of Physicians and Surgeons and a MS in Narrative Medicine from Columbia University. She completed her residency in internal medicine at Yale-New Haven Hospital, followed by her fellowship in general nephrology and advanced fellowship in glomerular disease at Columbia University Irving [...]

Editor’s Note: We asked authors of Original Investigations to provide short plain-language summaries that would briefly summarize what inspired their study, the basic approach taken, what was learned, and why it matters. We hope our readers will find this valuable in helping them keep up with the latest research in the field of nephrology. Highlights from the September 2026 issue: Utility of Risk Scores for Predicting Stroke and Intracranial Bleeding Across Levels of Kidney Function in [...]

For many years, the only specific pharmacologic intervention to decrease end-stage kidney disease in diabetic kidney disease was renin-angiotensin-aldosterone system blockade. Despite the addition of new interventions recently, there remains a need for new therapies. A recent Mini Review published in AJKD by Leehey and Agarwal takes a look at nonspecific phosphodiesterase inhibitor pentoxifylline, which has been shown to have antiproteinuric and anti-inflammatory effects, and small randomized [...]